TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07276373: Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Sponsor: Corcept Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT07276373 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07276373 Rescue Dossier →